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ABSTRACT 
Objective  Exploratory analysis of patients’ unsolicited written comments in the first 
2 years of the START trial Quality of Life (QL) study highlighted a potential effect of 
non-treatment related problems on the ratings and interpretation of patient self-
reported questionnaires. At 5 years’ follow-up all eligible subjects were invited to 
write comments to further explore these findings.  
 
Methods Using inductive qualitative methods informed by the exploratory analysis, 
comments were allocated to relevant themes. Key patient-reported outcome 
measures (PROMs), clinical and demographic factors were collated for patients 
who did and did not comment at 5 years and comparisons between the groups 
explored.  
 
Results Of 2208 women completing baseline PROMs, 482 proffered comments 
from 0-24 months forming 9 distinct themes, including chronic conditions, life 
events and psychosocial concerns. At 5 years, 1041/1727 (60.3%) women 
contributed comments, of whom 500 randomly-selected participants formed the 
sample for analysis. Findings revealed comorbidity, impaired physical functioning 
and psychosocial problems as key themes, with prevalent adverse effects from 
local and systemic treatments. Eight new themes emerged at 5 years included 
ageing, concerns about future cancer and positive aspects of care. Women 
commenting were better educated, slightly older and more likely to have had 
chemotherapy compared with non-commenters. They had significantly worse 
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PROMs scores for global health and key QL domains relevant to the difficulties 
they revealed.  
 
Conclusions Difficult personal circumstances and other health concerns affected 
many women’s PROM ratings at 5 years’ follow-up, in addition to on-going cancer 
treatment effects. Greater attention to multiple sources of distress and adversity 
could facilitate personalised care and aid interpretation of PROMs. 
 
Keywords 
Quality of life; patients’ free-text comments; contextual factors; breast cancer; 
radiotherapy; clinical trials 
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INTRODUCTION   
 
The findings of the START Trials Quality of Life (QL) substudy [1] provided valuable 
information for patients and clinical teams about beneficial and unfavourable effects 
of the radiotherapy treatment (RT) groups under comparison, as an aid to future 
decision-making and clinical care provision. START tested a widely-used dose 
regimen (40 Gy in 15 fractions) and two test schedules of hypofractionated 
radiotherapy (fractions >2.0 Gy) against the international standard of 50 Gy in 25 
fractions, in terms of local tumour control and late normal tissue effects. Findings 
from patients’ ratings strengthened the evidence in support of the clinical findings in 
favour of hypofractionated regimens [2,3], which influenced clinical breast 
radiotherapy practice [4]. The QL findings were derived from standardised 
measures designed within a biomedical framework, which included questions 
relating to protocol-specific RT effects that helped distinguish between the 
regimens.  
 
Such measures are very effective in supporting key endpoints in clinical trials and 
cover a range of largely biomedical domains to facilitate multidimensional 
comparisons between treatment arms and have contributed to clinical 
improvement. However they are not designed to encompass non-trial 
circumstances or individual experiences and so may not inform individual care. 
There has been extensive psychosocial research detailing the multiple and 
complex effects of breast cancer and its treatment [5-14], but to date there has 
been little opportunity for patients to express the meaning or relevance of non-
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breast cancer symptoms, psycho-social problems or functional limitations in the 
context of a clinical trial [5,15]. However it is expected that randomisation will 
eliminate any bias due to individual circumstances for treatment comparisons in the 
trial setting. 
 
Unexpectedly, during the first two years of Quality of Life (QL) data collection in the 
START trials, 22% of women wrote unsolicited comments at least once, or 
enclosed letters, when returning their QL booklets, These women frequently 
wanted to ‘explain’ that their responses to specific questionnaire items or subscales 
reflected the effects of other personal problems, life events or health issues rather 
than breast cancer or its treatment. Some women thought there should be space 
for such reporting: “Completing the questionnaire I thought there should be a 
question about whether there are any factors/worries in your daily life that affect 
your answers”. These patients also expressed concern that if contextual factors 
were sufficient to influence their questionnaire ratings they could be misattributed to 
effects of cancer treatments. The potential value of these comments in raising 
awareness of contextual problems in the clinical setting and of their possible 
influence on QL ratings warranted further exploration.  We therefore conducted a 
qualitative study of the comments proffered up to 2 years and a summary of the 
sample composition, analysis and findings is presented in Appendix A. These were 
found to endorse the importance to quality of life of comorbidity and other 
contextual factors, not captured by the QL measures, and the potential for 
misattribution of ratings to breast cancer outcomes. If generalised, these contextual 
factors could lead to inferior QL outcomes for long-term survivors in whom the 
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interplay of contextual factors, life stress and ageing may impede adjustment and 
be detrimental to coping, decision-making and ongoing self-management. [16,-19].  
 
Following on from this, and given the relatively small sample of women who 
proffered comments early on in the trial it was decided to invite comments from all 
women in the START trials completing PROMS at the 5-year assessment. The 
aims were: (a) to retrospectively explore reported health concerns and adverse 
contextual factors and see if they endorsed the proffered comments, and (b) to 
examine possible associations between QL scores derived from the quantitative 
questionnaire items and patients’ reported health concerns and other adverse 
contextual factors.  
 
MATERIAL AND METHODS 
 
Full details of the UK START trials and Quality of Life sub-study have been 
published separately [1-3].  The START trials were registered as an International 
Standard Randomised Controlled Trial, number ISRCTN59368779. Patients were 
recruited to the QL study from 31 of 35 radiotherapy centres in the UK between 
1998 and 2002 and the main quality of life outcomes were published in 2010 [1]. 
Ethical approval was obtained from the South Thames Multi-Research Ethics 
Committee to request additional written comments from all patients completing the 
5-year QL follow-up assessment; local ethics committees of all participating centres 
also gave approval. A blank page in the PROMS booklet was included and a 
patient information letter invited participants to report any health problems or events 
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that they thought might influence the answers they gave in their PROMS booklet 
(see Appendix B for full text).  
  
The QL booklets comprised the EORTC QLQ-C30 core questionnaire [20], EORTC 
QLQ-BR-23 breast cancer-specific module [21], Hospital Anxiety and Depression 
Scale (HADS) [22], Body Image Scale (BIS) [23] and a health economics 
evaluation [24], for completion at home. The trials office (ICR-CTSU) at the Institute 
of Cancer Research (ICR) first checked the individual’s current health status with 
their hospital team or family doctor before sending questionnaires. Prompts were 
sent for non-return of questionnaires by letter or telephone 3 weeks after mailing. At 
5 years, all pages with comments in the QL booklets were logged on the Quality of 
Life study data-base. 
 
The number of comments received on the 5-year questionnaires was too large to 
analyse using the entire written records and so comments from a random sample of 
500 patients were used for the analysis, which followed a constant comparative 
methodology [25], as described for the proffered comments (Appendix A). Thus, for 
each patient commenting, each written comment was allocated to an appropriate 
theme: initially all 9 themes created from the proffered comments analyses were 
used (Appendix A).. Additional themes were formed and labelled, for comments 
that had not previously been submitted. All decisions ascribing comments to ‘new’ 
themes were made jointly by at least 3 coders. Where there was difficulty allocating 
a theme a consensus decision was made.  
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Statistical Methods 
Descriptive analyses compared demographic and clinical characteristics, and key 
quality of life scores between women who did and did not provide comments at 5 
years. Quality of life subscale scores at 5 years were calculated as specified in the 
EORTC scoring manual [26]. 
 
A secondary analysis compared QL scores in 3 key domains (global health / QL, 
physical and emotional functioning)  and 2 symptom items (BR23 ‘hot flushes’ and 
‘worry about future health’) for women commenting on an associated theme with 
women who commented on different themes, to investigate associations between 
themes and corresponding quality of life scores. EORTC subscales were selected 
that were considered most likely to reflect differences between patients 
commenting or not commenting on key areas of concern, based on exploration of 
data from the proffered comments. For graphical presentation, the EORTC 
subscales were arbitrarily grouped into the following categories 0-40, 41-60, 61-80, 
81-100, as the distributions of scores were highly skewed.  
 
Differences were tested using either the t-test or Mann-Whitney test for continuous 
variables, or the 2 test or 2 test for trend for categorical variables, as appropriate.  
 
RESULTS 
At 5 years 91.2% (1728/1893) of eligible women completed QL questionnaire 
booklets and 60.2% (1041/1728) provided written comments; of these, 275/1041 
(26.4%) had also proffered comments between 0-24 months. Four patients in the 
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random sample selected for this analysis were excluded as their comments 
indicated only administrative issues. There were no clear differences between the 
randomised schedules in the proportion of women providing comments at 5 years. 
A comparison of the characteristics of women commenting or not commenting at 5 
years (Table 1) shows that ‘commenters’ were slightly older and better educated 
than ‘non-commenters’; they were more likely to have received adjuvant 
chemotherapy and had significantly poorer quality of life across all EORTC 
functional subscales, and worse fatigue and pain symptom scores.  
 
Seventeen themes emerged from the 5-year comments (see Table 2 and Appendix 
B), including nine derived from the unsolicited comments (see Table A.2 in 
Appendix A). The number of themes reported per person ranged from 1 to 9 
(Figure 1).  
 
The ‘Chronic medical and physical functioning’ themes were combined at 5 years 
due to frequent overlap of reported conditions; this was the most frequently used 
theme (34.3% women commented) compared with 26% reporting local breast 
related problems and  21.8% commenting on systemic treatment-related problems. 
In contrast to earlier proffered comments these local and systemic treatment- 
concerns were expectedly more prevalent at 5 years. The personal and individual 
impact of treatment related problems varied widely, highlighting their adverse 
impact on well-being, bodily changes, social activity, sex life, and satisfaction.  
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One in six women reported current or chronic mental health difficulties, usually 
unrelated to cancer, whilst job problems, life events and family problems were less 
prevalent at 5 years than earlier in the trial. New themes included concerns about a 
cancer family history (reported by only 2.8%), ageing effects (8.1%) or concerns 
about the future (11%), especially fears of recurrence. Both dissatisfaction and 
satisfaction with medical and hospital care were expressed. Overall, two thirds of all 
written comments were negative or expressed difficulties and concerns. However, 
at this final 5-year assessment point in the START trials 30% of written comments 
were brief remarks of gratitude for positive aspects of care and appreciation of trial 
participation; others reflected the value of personal support, positive life events and 
of making a good recovery (16.1%). (Appendix B shows examples from all  the 
themes at 5 years).  
 
Comparing quantitative QL ratings between groups of women commenting on 
specific areas of concern, Physical Functioning and Global Health/QL scores were 
significantly worse for women who commented in the ‘Chronic Medical and 
Physical Functioning’ theme compared with women who had commented in 
different themes (Figures 2a and 2b). Similar QL differences for Emotional 
Functioning and Global Health/QL were found for women commenting versus those 
not commenting  in the ‘Psychological problems’ theme (Figures 2c and 2d). 
Further, significantly more women (34%) commenting on systemic treatment side 
effects rated their  ‘hot flushes’ in the BR23 subscale  as ‘quite a bit’ or ‘very much’) 
compared with 24.8% of ‘non-commenters’ on this item (p=0.018). Scores on the 
BR23 ‘future perspective’ item were significantly worse for those commenting on 
their personal fear of recurrence (45.3% responded ‘quite a bit’ or ‘very much’) 
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compared with women who did not comment in this theme (31.6%  responded  
‘quite a bit’ or very much’, (p=0.016). 
 
Discussion 
Women’s free-text comments in the START trials revealed many adverse personal 
circumstances at 5 years’ follow-up as well as current and chronic health and 
psychosocial difficulties. For some women, breast cancer was not the only – or 
necessarily the main - determinant of their quality of life. For others, ongoing or late 
effects of multimodal breast cancer treatment significantly impaired their well-being. 
Overall, these comments endorsed and extended the proffered comments made by 
women earlier in the trial. They provide a broad, explanatory dimension to their 
quality of life ratings, and highlight negative effects of co-morbidity, life events and 
adverse psychosocial problems on many individual experiences of cancer and 
quality of life outcomes. These insights from a national radiotherapy trial setting are 
novel and informative but also resonate with many issues described by others, 
using examples from clinical research and practice and patients’ testimonies [6,7]. 
From these, wide-ranging contextual factors were uncovered that were considered 
critical to understanding patients’ resources and experience of cancer.   
 
We confirmed a significant negative impact on quality of life ratings for 
‘commenters’ compared with ‘non-commenters’ over all functional domains, as well 
as specificity of the effect of particular themes on related QL domains.  Comments 
on psychological problems often referred to specific reasons for their QL ratings 
such as chronic mental health, family problems and general stress rather than 
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breast cancer, adding informative value to an earlier assessment of psychological 
problems in the START trials [27]. Adverse effects of local and systemic breast 
cancer treatment effects were expressed by women in their comments in addition 
to completing QL questions in these key areas, adding personal details of the 
impact of these treatment effects, such as on body image and sexuality. Comments 
about chronic or disabling conditions and co-morbidities were expectedly frequent 
in an ageing population and reflect evidence of both incident and chronic disease in 
survivors [13], These conditions are of concern as they can lead to an inferior 
prognosis and worse disease outcomes [13, 19, 28], as well as indicating 
supportive care needs.  
 
Comments about fear of recurrence and existential concerns were the most 
prevalent in the new themes at 5 years and have been highlighted as a key 
problem in recent research [29,30]; other new issues reported may reflect women’s 
increased awareness of genetic aspects, second cancers and the effects of ageing 
during survivorship. Expressions of positive outcomes and praise for health care 
and trial participation demonstrated good supportive care in the trials setting and far 
outweighed criticisms.   
 
What are the implications for future QL assessment? 
Many issues raised in the written comments were not covered by the PROMS and 
this calls into question the scope and interpretation of quality of life data in future 
RT trials. However the strength of these measures in the START trials was in 
determining selected biomedical outcomes from thousands of patients’ ratings to 
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determine differences between the treatment regimens, enhancing the clinical 
findings; other studies have found an association of PROMS with improved 
supportive care and patient satisfaction [31]. However these questionnaires are not 
designed to differentiate between breast-cancer-related and more general health or 
contextual problems. Concerns have been raised about the selected agenda of QL 
measures [15], which limit the discovery of additional influences on wellbeing [7]. It 
has been suggested that the assessment in clinical trials needs to be broadened to 
include environmental, economic, medical and social factors [6,7,15 32].  Moreover 
with few exceptions [33], symptoms are reported in PROMS in terms of their 
occurrence and severity over time rather than the distress or disruption caused to 
daily life. 
  
What is the value of self-reported comments?  
 Women’s comments reveal the experience of cancer and the impact of adverse 
events and day to day difficulties, as well as the interrelatedness of health and 
personal or social circumstances. For example, losing a job after diagnosis can 
lead to developing depression. However, distinctions between the contribution of 
treatment and other causes (comorbidity, physiologic) to reported symptoms can 
still be difficult to determine. The value of this additional information extends 
beyond the randomised comparisons. However, can patients’ free-text comments 
continue to make a valid contribution? Their utility has been endorsed in a large 
exploratory study of patients’ views of cancer care [34] in which the potential value 
of free-text comments was described as ‘illuminating’ when highlighting potential 
causes for some inferior outcomes in a survey of mixed cancer patients [35].  Novel 
ways of analysis of these data have also been described [36]. However free-text 
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comments usually require a time-consuming methodology and analysis which is 
likely to preclude frequent use in large studies. Currently free-text comments are 
being invited in two further RT trials run by The Institute of Cancer Research in 
order to explore earlier stages of treatment and follow-up for which adequate data 
was not available in the START trials.  
 
In support of our findings we found no significant difference between the different 
treatment schedules of the START trials in terms of frequencies of comments and 
can therefore be confident that there was no specific bias to the QL results on that 
basis. The QL sample gave good representation with respect to age and 
geographic area for breast cancer populations [37]. Using a constant comparative 
methodology enabled us to describe comments on the diverse social and medical 
context of women’s breast cancer experience by creating distinct themes, but not to 
speculate on whether these women would be similar to age-matched population 
samples. We do not know if women commenting also reported and discussed their 
concerns with health professionals or received helpful interventions.  
 
Considering potential confounders in our study, we recognise that women who 
chose not to comment may have felt non-cancer problems were irrelevant or 
inappropriate. Their apparent enhanced quality of life may reflect more adaptive 
coping, favourable resilience or adjustment to adversity. Beneficial effects of 
existing social care, psychological or medical intervention may also play a part. 
Women commenting were better educated and slightly older which may have 
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enhanced response rates whilst those receiving chemotherapy perhaps felt more 
impetus to report related problems.  
 
In conclusion, this novel opportunity to synthesise quantitative and qualitative data 
in the START trials provides a broader understanding of the cancer experience and 
the influence of acute and chronic contextual problems. Awareness of our findings 
should help clinical teams to address the wider effects of contextual difficulties, 
comorbidity and late effects of treatment, and stimulate thought about the 
interpretation and future development of PROMs. Many women accept trial 
participation for altruistic reasons [38] and their feedback should help inform the 
provision of individualised supportive care for future patients. 
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Figure legends 
 
Figure 1: Number of themes identified per person from the random sample of 500 
women commenting at 5 years  
 
Figure 2: Specificity of themes derived from comments provided at 5 years with 
corresponding 5 year EORTC QLQ-C30 subscale scores  
Scores range from 0-100: higher scores indicate better functioning and global 
health Denominators vary due to missing data for some QL subscales 
 
Figure 2a:  Physical Functioning subscale scores for women commenting / not 
commenting about chronic medical problems  
Figure 2b:  Global Health / Quality of Life subscale scores for women commenting 
/ not commenting about chronic medical problems  
Figure 2c: Emotional Functioning subscale scores for women commenting / not 
commenting about psychological problems  
Figure 2d:  Global Health / Quality of Life subscale scores for women commenting 
/ not commenting about psychological problems  
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Figure 2 
 
Figure 2a: Physical functioning 
 
Figure 2b: Global health / QL 
 
Figure 2c: Emotional functioning 
 
Figure 2d: Global health / QL 
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Table 1:  Characteristics of women who wrote comments at 5 years and women who 
did not 
 Women who 
commented at 
5 years) 
N=1041 (%) 
 
Women who 
returned 5-year  
form but who did not 
comment 
N=687 (%) 
p-value 
Age at baseline (years): mean 
(SD) [range] 
57.4 (10.0) 
[27-85] 
56.2 (9.8) 
[28-82] 
0.0211 
Highest level of education 
achieved3 
  <0.0012 
None; 
School certificate / O-level / GCSE       
/ NVQ or equivalent; 
A-level / HND or equivalent; 
Degree, post-graduate or 
professional qualification; 
Unknown – not completed on form 
326/981 (33.2) 
275/981 (28.0) 
60/981 (6.1) 
 
282/981 (28.7) 
 
38/981 (3.9) 
284/624 (45.5) 
185/624 (29.6) 
30/624 (4.8) 
 
97/624 (15.5) 
 
28/624 (4.5) 
 
Type of surgery    0.1053 
Breast-conserving surgery 906 (87.0) 578 (84.1)  
Mastectomy 135 (13.0) 109 (15.9)  
Chemotherapy   0.0253 
No 746 (71.7) 454 (66.1)  
Yes 
Unknown 
295 (28.3) 
0 
229 (33.3) 
4 (0.6) 
 
Tamoxifen   0.1383 
No 161 (15.5) 125 (18.2)  
Yes 
Unknown 
880 (84.5) 
0 
558 (81.2) 
4 (0.6) 
 
EORTC QLQ-C30 subscale scores at 5 years4: 
Global heath / QoL 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
76 (7.3) 
204 (19.6) 
267 (25.6) 
489 (47.0) 
5 (0.5) 
 
34 (4.9) 
102 (14.8) 
167 (24.3) 
379 (55.2) 
5 (0.7) 
<0.0012 
Physical functioning 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
41 (3.9) 
105 (10.1) 
228 (21.9) 
666 (64.0) 
1 (0.1) 
 
19 (2.8) 
43 (6.3) 
115 (16.7) 
508 (73.9) 
2 (0.3) 
<0.0012 
Emotional functioning 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
46 (4.4) 
129 (12.4) 
284 (27.3) 
579 (55.6) 
3 (0.3) 
 
32 (4.7) 
53 (7.7) 
172 (25.0) 
424 (61.7) 
6 (0.9) 
0.0112 
Role functioning 
0-40 
41-60 
61-80 
 
103 (9.9) 
46 (4.4) 
183 (17.6) 
 
33 (4.8) 
18 (2.6) 
79 (11.5) 
<0.0012 
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SD= standard deviation. Unknown categories excluded from significance tests.  
 
1 t-test; 2 2 test for trend; 3 2 test;   4 Education data collected at 1 year after 
randomisation, so not available for all participants; 4 EORTC QLQ-C30 scores range from 
0-100: higher scores indicate better functioning but worse symptoms  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81-100 
Unknown 
705 (67.7) 
4 (0.4) 
552 (80.3) 
5 (0.7) 
Social functioning 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
59 (5.7) 
41 (3.9) 
136 (13.1) 
802 (77.0) 
3 (0.3) 
 
22 (3.2) 
9 (1.3) 
63 (9.2) 
588 (85.6) 
5 (0.7) 
<0.0012 
Cognitive functioning 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
44 (4.2) 
67 (6.4) 
200 (19.2) 
727 (69.8) 
3 (0.3) 
 
22 (3.2) 
28 (4.1) 
117 (17.0) 
515 (75.0) 
5 (0.7) 
0.0092 
Fatigue symptoms 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
793 (76.2) 
167 (16.0) 
59 (5.7) 
21 (2.0) 
1 (0.1) 
 
578 (84.1) 
67 (9.8) 
30 (4.4) 
10 (1.5) 
2 (0.3) 
0.0012 
Pain symptoms 
0-40 
41-60 
61-80 
81-100 
Unknown 
 
859 (82.5) 
71 (6.8) 
70 (6.7) 
40 (3.8) 
1 (0.1) 
 
618 (90.0) 
34 (4.9) 
17 (2.5) 
15 (2.2) 
3 (0.4) 
<0.0012 
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Table 2:  Themes derived from women’s invited comments at 5 years, showing most 
frequent component items, for the random sample of women who commented 
 
 
NEGATIVE COMMENTS 
Number (% of 496) 
of women reporting 
theme at 5 years 
Chronic medical problems including physical 
functioning: 
Asthma, breathlessness, diabetes, heart disease, 
hypertension, chronic conditions e.g. multiple sclerosis. 
migraine, Parkinson’s disease, rheumatoid and osteoarthritis, 
fractures or falls, back or joint pain, fibromyalgia, muscle pain 
or injury, mobility problems 
 
170  (34.3) 
Breast   Breast and related problems: 
Breast pain, arm lymphoedema, cancer recurrence in the 
breast, breast abnormalities, radiotherapy effects to the 
breast, body image 
129 (26.0) 
Systemic treatment side effects:  
Tamoxifen side effects, hot sweats, weight gain, sexual 
problems 
108 (21.8) 
Surgery (excl. breast cancer related surgery) & Hospital 
Admissions  
Gynaecological, dental, or other surgery, orthopaedic, falls 
28 (5.6) 
Acute or transient health problems: 
Colds, viral infections, ‘stomach upset’ 
47 (9.5) 
Psychological problems:  
Depression or taking antidepressant medication, history 
of mental illness (e.g. schizophrenia) anxiety disorders, 
panic attacks, stress 
89 (17.9) 
Life events or family problems: 
Bereavement, husband’s illness, house move, relationship 
problem 
43 (8.7) 
Job problems:  
Redundancy, early retirement, job loss and other job related 
issues  
10 (2.0) 
Other cancers: 
Any cancer other than second primary breast cancer / 
recurrence / metastasis 
12 (2.4) 
Aspects of Care: 
Problems with diagnosis, treatment or follow-up, GP or 
specialist  
17 (3.4) 
Family history of cancer: 
Family members with cancer, genetic risk 
14 (2.8) 
Effects of aging: 
Older age affecting recovery, uncertain symptom attribution, 
e.g. tiredness 
40 (8.1) 
Future concerns:  55 (11.1) 
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Cancer related worries, fear of cancer recurrence 
POSITIVE COMMENTS  
Good aspects of care: 
Gratitude to hospital staff and trials unit, felt well supported 
149 (30.0) 
Good recovery from cancer: 
Feeling back to normal, positive attitude 
80 (16.1) 
Personal support: 
Support from friends, family, GP, religion 
27 (5.4) 
Positive life events: 
e.g. grandchildren, family births, marriage 
16 (3.2) 
 
Percentages add up to >100% as some women have commented in more than one category 
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Supplementary Material 
Appendix A: A preliminary exploration of proffered comments received 
between 0 and 24 months in the Quality of Life substudy in the START trials 
 
Methods 
Unsolicited letters or comments written in the QL booklets received between 0 and 
24 months in the START trials quality of Life substudy were abstracted and typed 
verbatim for each patient (identified by their study ID) for each time point, in order 
to explore their content in more detail. 
 
An inductive qualitative methodology described by Pope (2000) was used to create 
themes for collating comparable comments. The initial analysis of unsolicited 
comments was carried out by 2 coders (JM,PH), with overall guidance from an 
expert qualitative researcher (CM). Each comment was allocated to an appropriate 
theme created by the first author (JM) and reviewed by a second researcher (PH), 
A constant comparative method was used, where verbatim reports were compared 
both within and between participants’ responses, to identify independent themes 
from their content. Where a theme was unclear, the classification was reviewed 
jointly until agreement was reached. 
 
Many comments were written alongside a specific QL questionnaire item or 
subscale, which helped determine the appropriate theme. The patient’s exact 
wording provided the over-riding factor in guiding categorisation, for example   
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”Most of my concerns are caused by work rather than my illness and treatment"  
would be categorised as a work-related comment. 
 
Multiple comments from an individual patient were included in more than one 
category.  For example: “My life has changed drastically since I was diagnosed but 
it had nothing to do with my breast cancer…. Firstly I moved home, then my mother 
died, followed by my husband’s death and finally with eye surgery and a diagnosis 
of arthritis……” In this case the comments were allocated to three themes, ‘life 
events’, ‘chronic medical/mobility’ and ‘surgery’. 
 
Comments of a practical nature (such as apologies for late return of the 
questionnaire) were not coded. No assumptions were made about a concern or 
symptom having an enduring effect time (e.g. possible chronic disability or 
permanent functional difficulty) and no weighting was given to any of the proffered 
explanatory comments received.  
   
Results 
Overall, 22% of women (482/2181) with evaluable data in the quality of life sub 
study proffered written comments in their booklets, or included letters, at least once 
between baseline and two years follow-up., increasing over time. The number of 
women making comments at baseline, 6, 12 and 24 months was 97/2181 (4.4%), 
180/2046 (8.8%), 175/1985 (8.8%) and 236/1888 (12.5%) respectively. 
Characteristics of the overall trial cohort and the subgroup commenting over this 
time are shown in Table A.1 of this appendix. This shows broad comparability with 
 33 
the overall trial cohort.  Differences observed were generally small but statistical 
testing was not deemed reliable given the unselected nature of the women making 
comments.  
 
Nine themes were created (Table A.2 in this appendix) and were relatively 
straightforward to identify; examples are shown in this appendix. Physical 
functioning and chronic medical problems were the most frequently used themes 
but psychological problems and life events / family problems were also often 
reported. These accounted for the majority of contextual life difficulties reported, 
many of which are not reflected in the self-report QL measures. Women frequently 
wrote alongside the relevant questionnaire item or PROM domain indicating that 
their rating reflected a non-cancer / non-treatment cause and wanted us to be 
aware of that.  
 
Questions in the health economics section of the QL booklet concerning work 
status at one year follow-up showed that 77% women (834/1107) had returned to 
work at this point. Work status was unknown for 213 women and 580 were retired 
at baseline, but of those not returning to work 70 (50% of non-returnees) made 
explanatory comments, such as ‘ill health’, ‘made redundant’, ‘retired early’, or 
‘business closed’.  
  
To investigate the women’s concerns that their contextual problems may negatively 
affect associated QL ratings, we compared the EORTC functional domains and 
HADS Anxiety and Depression subscale scores for women commenting at the 
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same assessment point with those of women who did not comment on that 
occasion.   These showed differences in the expected direction, that is, worse 
scores for women commenting on their concerns or contextual difficulties, for all 
variables (Data not shown). However, as the women commenting were a self-
selected group, this was not deemed a reliable basis for inferring QL outcomes. 
        
Implications 
Women’s spontaneous comments, written in a naturalistic, unsolicited setting, 
highlighted concerns and situations in their lives that have been widely shown to 
affect the quality of life of breast cancer patients. They reflect the importance of the 
social context in the clinical trials setting and are relevant to the provision of support 
and holistic care.  Such findings, if consistent in other trial patients, might 
encourage a more cautious interpretation of secondary endpoints in clinical trials 
such as START. 
 
Therefore a decision was made to invite all patients to contribute comments at the 
final 5-year assessment, saying “If you wish to write comments about any 
concerns, health problems or events which you think might affect the answers you 
give in the QL booklet, please do so”. This new analysis of invited comments is fully 
reported in the main paper.  
 
References 
Pope C Ziebland S, Mays N.  Qualitative research in healthcare: Analysing 
qualitative data.  BMJ 2000; 320: 7227. 114 
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Themes derived from proffered comments (0-24 months follow-up), with 
examples 
 
Physical Functioning 
‘I had difficulty completing the form as not sure which questions refer to breast 
cancer and which to general health. I have a crushed vertebra, which causes me 
considerable pain and discomfort.  I suffer no pain from radiotherapy’ 
‘I should stress that all slowness and extra time taken on simple tasks stems from a 
worsening hip condition.  I am still waiting for a hip operation when I hope my 
mobility will be better next time you send me questions’ 
 
Chronic medical problems 
‘I may be wrong but I feel any health symptoms I have are more to do with my heart 
problem, e.g. walking, breathing during strenuous activities, than my breast 
lumpectomy.  I hope you will allow for this in my answers’ 
‘Because I suffer from a mild form of MS my state of health depends on a level of 
fatigue.  I don’t think the cancer treatment has changed anything’ 
 
Breast related problems 
‘After my operation, I came home and a nurse told me that my breast was infected, 
it really hurt and I had to return to have my breast drained, a very painful 
experience’  
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‘I have been unable to answer some of the questions properly as a cancer was 
found in the other breast, a different type of cancer, it was removed and I now 
receive chemotherapy.  I have no discomfort from the last cancer nor the 
radiotherapy’ 
 
Systemic treatment effects 
‘I have come off tamoxifen as I put on loads of weight and my eyesight has been 
affected, also the hot flushes have been horrendous.  I just wanted to make it clear 
why I’m dissatisfied with my appearance and why sometimes I’m a bit low’ 
‘Please note that a lot of my replies are due to tiredness caused by difficulty 
sleeping.  This is likely to be caused by the tamoxifen’ 
 
Surgery 
‘A lot of my answers are affected by the fact that I had major heart surgery to have 
a mechanical heart valve replacement only 10 weeks before I had a mastectomy’ 
‘Problems relate to hysterectomy operation. Still recovering’ 
 
Acute and transient health problems 
‘The past week has definitely not been my ‘best week’.  I went down with a heavy 
cold and awful cough’  
‘Recovering from shingles which was very painful and my answers reflect this’ 
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Psychological problems 
‘I have been taking prozac since diagnosis and feel that this has affected my mood.  
I have experienced a change of mood since stopping HRT and commencing 
Tamoxifen  with a return of menopausal symptoms’ 
‘I have been feeling anxious and my GP has prescribed Seroxat tablets which I 
have been told will take a month or so to have an effect.  So far I have been taking 
them for 2 weeks so hopefully when I complete the next booklet I will be feeling 
fine’. 
 
Life events 
‘My husband left me 2 weeks after surgery (not connected to surgery) and during 
my chemotherapy I got divorced….’ 
‘My mother has also recently learnt that two of her cousins (on her mother’s side of 
the family) have also had breast cancer…’ 
 
Job problems 
 ‘I was extremely stressed by bullying in my work place before I was diagnosed.  I 
have not yet returned to work but I am still emotionally affected by visits and phone 
calls from my employers Most of my concerns are caused by work rather than my 
illness and treatment’ 
‘I returned to work for a period of two months only, before being signed off sick 
again…  I eventually had to let the job go, as recommended by my doctor’ 
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More than one theme 
‘My life has changed drastically since I was diagnosed with breast cancer in 2000 
but nothing to do with the breast cancer.  Firstly I moved home, then my mother 
died, followed by my husband’s death, and finally with eye surgery, and a diagnosis 
of arthritis for which I take strong painkillers’ 
‘I feel tense or ‘wound up’ because I am looking after my 96 year old Aunt.  I look 
forward with enjoyment to things rather less than I used to, because of my arthritis.  
Also my husband has prostate cancer’ 
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Table A.1: Characteristics of patients who proffered comments at 2 years and 
for the overall QL cohort enrolled in the START Trials Quality of Life study 
 
  Overall Cohort 
N= 2208 (%) 
Proffered 
comments  
subgroup (0-2 
years) 
N= 482 (%) 
Age at baseline (years): mean (SD) [range] 56.9 (10.4) 
[26-86] 
57.6 (10.6) 
[28-81] 
Highest level of education achieved1 
School certificate / O-level / GCSE / NVQ or 
equivalent 
528/1899 (27.8) 114/438 (26.0) 
A-Level / HND or equivalent 115/1899 (6.1) 31/438 (7.1) 
Degree, post-graduate or professional 
qualification 
439/1899 (23.1) 124/438 (28.3) 
None of the above 725/1899 (38.2) 151/438 (34.5) 
Unknown – not completed on form 92/1899 (4.8) 18/438 (4.1) 
Employment prior to diagnosis1  
Full-time 540/1899 (28.4) 130/438 (29.7) 
Part-time 443/1899 (23.3) 87/438 (19.9) 
Self-employed 132/1899 (7.0) 33/438 (7.5) 
Retired or household work 1095/1899 (57.7) 263/438 (60.0) 
Other (voluntary, job-seeking, student, sick 
leave) 
281/1899 (14.8) 79/438 (18.0) 
Unknown – not completed on form 41/1899 (2.2) 6/438 (1.4) 
Type of surgery  
Breast-conserving surgery 1831 (82.9) 392 (81.3) 
Mastectomy 377 (17.1) 90 (18.7) 
Adjuvant systemic therapy 
None 128 (5.8) 32 (6.6) 
Chemotherapy alone 224 (10.1) 50 (10.4) 
Tamoxifen alone 1266 (57.3) 267 (55.4) 
Chemotherapy & Tamoxifen 537 (24.3) 118 (24.5) 
Other 42 (1.9) 14 (2.9) 
Unknown 11 (0.5) 1 (0.2) 
Global heath/QoL during past week at 
baseline2: median (IQR) 
66.7 (56.2-83.3) 66.7 (50.0-83.3) 
 
SD= standard deviation, IQR=interquartile range  
 
1 Education and employment data collected at 1 year after randomisation, so not 
available for all participants (1899 and 438 1-year forms completed for overall 
cohort and 2-year proffered comments group respectively). Women could tick more 
than one employment category, hence percentages add up to >100%. 
 
2 Subscale from EORTC QLQ-C30; score ranges from 0-100, with higher scores 
indicating better global health / quality of life. 
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Table A.2: Themes derived from women’s proffered comments showing most 
frequent component topics, received between baseline and 2 years’ follow-up 
in the START Trials 
 
 
Physical functioning:  
Arthritis (rheumatoid and osteoarthritis) fractures or falls, back or joint 
pain, fibromyalgia, muscle pain or injury, mobility problems 
Chronic medical problems:  
Asthma, breathlessness, diabetes, heart disease, hypertension, skin 
rashes, drug reactions (excluding Tamoxifen or other cancer therapies), 
chronic conditions e.g. MS. Migraine, Parkinson’s disease 
Breast and related problems: 
 Arm lymphoedema, cancer recurrence in the breast, radiotherapy 
effects on the breast 
Systemic treatment side effects: 
Weight gain, hot sweats ‘tamoxifen side effects’ 
Surgery (excluding breast cancer related): 
 Gynaecological, dental, or other surgery. 
Acute or transient health problems: 
Colds, viral infection, ‘stomach bug’ 
Psychological problems:  
Depression or taking antidepressant medication, history of chronic 
mental illness (e.g. schizophrenia) anxiety disorders, panic attacks 
Life events or family problems:  
Bereavement, husband’s illness, house move 
Job problems:1  
Redundancy, early retirement, job loss and other job related issues 
 
1Only collected in years 1 and 2 
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Appendix B:  Themes & Examples of Comments made at 5 Years in the 
START Trials 
 
Instructions given: 
Written at the top of a blank page in the 5-year Quality of Life booklet: “Please feel 
free to add your own comments.  We will be very pleased to have them”  
A letter to every patient was enclosed with the 5-year QL Booklet, saying:  ‘If you 
wish to write comments about any concerns, health problems or events which you 
think might affect the answers you give in the QL booklet, please do so.  You will 
find a blank sheet of paper at the end of the booklet. This is entirely voluntary, but 
please feel free to write as little or as much as you want.  Your comments will, of 
course, remain anonymous and confidential but they may be used to help inform 
doctors and nurses about the results of the study in publications and we will ensure 
you cannot be identified by them.’ 
 
Chronic Medical problems and physical functioning 
‘Any negative replies I have given do not refer to my breast cancer treatment, but 
totally unconnected medical problems’ 
‘Osteoporosis and IBS cause pain in my lower body. Not worried about breast 
cancer and doing OK’ 
‘I suffer from diabetes, heart disease and IBS, this will have affected answers’ 
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Breast and related problems 
‘My main problems have been about the use of my right arm, post axillary 
clearance and this does limit my use of that arm for carrying bags and swimming, 
rowing etc’ 
‘I have had further recurrences of cancer. I found lumps under my other arm, all 
were cancerous. Had a second mastectomy. Feel as if living with a time bomb’ 
‘I feel self-conscious about my breast as red lines around armpit from RT and black 
ring around nipple’ 
 ‘The skin problems with my affected breast are chiefly the noticeable outline of the 
radiotherapy area, which I understood would disappear in 6 to 12 months after 
cessations of treatment, but which now looks as if it will be a permanent feature’ 
 
Systemic treatment side effects 
‘I was on Tamoxifen for 2years and Arimidex for 3 years…. these have made my 
life extremely uncomfortable and none of the remedies worked.  This had a huge 
negative effect on sleeping, sex, weight-gain, morale and self-esteem as well as 
general life.....However the quality of life, even after cancer should be treated with 
equal importance and one should not be made to feel ‘lucky to be alive!’ 
‘The on-going problem of hot flushes has severely restricted my social life and also 
relationships with others’ 
‘I feel cheated that the drugs took away all sexual desire....  Now at 57 my sex life 
will never return. But mentally I feel I should be enjoying sex’ 
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Surgery (excluding breast cancer related surgery) and Hospital Admissions 
‘I had a knee replacement in July. Had mild ulcerate colitis in Oct and admitted to 
hospital last week, this affects answers’ 
‘Until this year felt very well, active and looking forward to a holiday of a lifetime. 
Then I was rushed to Hospital for keyhole surgery and they found an ovarian cyst. 
Been off work since’ 
‘I have recently been in car accident and suffered a fractured sternum and 
whiplash. At present unable to carry out normal duties at home and work’ 
 
Acute or transient health problems 
‘Suffering from double vision following eye tests. Awaiting results which is giving 
me anxiety..’  
‘My health and quality of life affected by cough and cold virus also sore throat which 
has kept me awake at night’ 
‘These answers are not a true reflection of my breast cancer. I have had flu for the 
past week and am still recovering’ 
 
Psychological problems  
‘Carer for husband for 10 yrs. Mood swings due to his illness’ 
‘Felt quite low for some time, could be due to a lot of trouble at home with some of 
the family and nothing to do with my cancer…’ 
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‘My tension is nothing to do with my breast cancer. It is to do with my husband who 
wishes to spend retirement abroad. I don't wish to leave this country, friends & 
family. Causing tension and anxiety’ 
 
Life Events:  General and Family problems 
‘Just lost youngest daughter (39 years) to cancer’ 
‘Since RT I have moved house, lost my husband, moved again, started part time 
business and met a new partner. Much of my anxiety or worry has been attributed 
to these life experiences’ 
‘Widowed last year, which has affected my answers’ 
 
Life Events: Job problems:  
‘After diagnosis I lost my job. I believe that there was a connection and that led to 
my depression and anxiety’ 
‘I am tired a lot of time and feel unable to work and pursue leisure activities’ 
‘I am uncertain about the future in relation to work. The saying "the misery of 
certainty is far worse than the certainty of misery’ 
 
Other cancers 
‘I now have bowel cancer’ 
‘I have been diagnosed with cancer of the ovary’ 
‘I have acute myeloid leukaemia’  
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Aspects of Care (negative)  
‘Delay in initial treatment, GP did not refer me for a year. Feelings of anger added 
to distress & anxiety’ 
‘I’ve never seen my consultant and felt that everything was rushed and would have 
liked to speak to a breast care nurse about the alternative treatments….’  
‘Not enough support given when treatment is finished. More help should be given’  
 
Family History of Cancer 
‘I am v anxious and depressed because cancer is rife in my family’  
‘Work part-time, I am tired and anxious as family history of breast /ovarian cancer 
‘My sister died 10 yrs after diagnosis with ovarian cancer so it’s at the back of my 
mind’ 
 
Effects of Ageing 
‘I find it difficult to distinguish whether any minor problems are due to cancer 
treatment or to getting older e.g. occasional forgetfulness, weight gain’ 
‘My aches & pains are due to age rather than treatment. Delighted with the team 
that took care of me. Health at my age is v good’ 
‘My health problems are to do with age and arthritis’  
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Future concerns: Cancer related worries  
‘In the last 6 months, 2 of my friends have died from breast cancer and another 
friend is in a hospice........  Mostly I consider myself to be well and cured of the 
illness, but from time to time I remember what I’ve been through and wonder what 
the future holds especially when I see my friends suffering’ 
‘Even now 5 years on, I am very worried and sometimes I can’t sleep properly, it is 
always on my mind’ 
‘When I stopped Tamoxifen I felt very frightened, and worried that the cancer would 
re-occur.  I felt as if a safety net had been pulled from under me’ 
 
Positive Comments: 
Good Aspects of Care 
‘Thanks for care and support during the 5 years’ 
‘Been interesting doing the trial. Made me think about my health and well-being’ 
‘Cancer turned out to be blessing’ 
‘Pleased to have been part of the trial and hope it helps in some way’ 
 
Good Recovery from Cancer 
‘I remain positive, have an excellent social circle and enjoy my life.  Cancer has 
given me a very positive outlook on life, I realise the value of friendship, grabbing 
opportunities and living each day to the full’ 
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‘I’ve changed my outlook to life – I take this as a wake-up call to appreciate life and 
to look after myself more carefully in terms of food and exercise. Through my 
treatment I was always worrying “what if" in case it came back. Now I've been 
discharged I feel a sense of relief to get on with life’ 
‘I’ve tried to look into more spiritual and positive things in life and get on to life in a 
positive way’ 
 
Personal Support (friends, family, GP, religion) 
‘Everyone has been so kind and happy to answer any questions and fears I had. I 
am a Christian and feel that my faith has played a vital part in my recovery’ 
‘I have a positive attitude to most things and with the help of a loving family, great 
friends and neighbours with plenty of interests inside the home and outside’ 
‘I have had a positive attitude the whole time and a lot of help from family, quite 
sure that helped.  Plus most important of all I have real faith in God, in a very quiet 
way’  
 
Positive Life Events 
‘Recently completed a degree which has helped with my feelings of wellbeing & 
self-esteem. Each day feel stronger and more alive’  
‘Breast cancer has not held me back. 6 months walking in India’  
‘I have now qualified as a teacher, a new life and partner’ 
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Mixed Comments (not mentioned in table) 
‘Reconstruction (flap) has made a big difference, helped mentally. Felt depressed 
for other factors unrelated to health. Hot flushes improved and now stopped tam 
and hopefully lose some weight. Good thing about breast cancer has been the 
focus on important things in life’ 
‘Have arthritis therefore trouble with a long walk. Have diabetes so feel nauseas at 
times. Treated for depression with Prozac for 9mnths. Now feel great look forward 
to future and consider myself very fortunate’ 
‘Suffer slightly from depression 3 months after radiotherapy onwards and 
continuing. Receiving anti-depressants for anxiety stress and headaches. 
Information from the team was excellent. Completing the questionnaires has helped 
in appreciating how far I’ve progressed in 5 years’ 
 
Comments about commenting 
‘I have a few symptoms unrelated to breast cancer. Facial nerve spasm affects my 
eyes. Q does not give an opportunity to say if any aspects of current health are felt 
to be linked with breast cancer. ‘ 
‘Very concerned no questions asking other factors in my life. One problem was 
telling already stressed family members of my health problems - made my life even 
more difficult’ 
 
 
